Top > News Releases
January 13, 2009
An internet site, Science-Business eXchange which was managed by BioCentury and Nature published that YSPSL would be a potent anti-elilepsy drug.
Here is cited image from SciBX-January 8, 2009 ↓
【Figure】 Triggering a seizure.
【Comment】 YSPSL / Stefan Hemmerich
About Y's Therapeutics
Y's Therapeutics (http://www.ysthera.com) is a privately held biopharmaceutical company engaged
in the R&D of novel therapeutics for the treatment of inflammation-mediated diseases, cancer, and other unmet medical needs.
Y's focuses on the development of preclinical and early-stage clinical projects pursued through research collaborations and
in-licensing opportunities from academic institutions and biotech companies. Y's is seeking collaborative relationships,
including out-licensing of product rights and creation of joint ventures, for late-stage development,
manufacturing and commercialization of its portfolio products. The company currently has several projects
in its clinical and preclinical pipeline. Y's has operations in two locations, Y's Therapeutics Co., Ltd.,
of Tokyo, Japan, and Y's Therapeutics, Inc., of Burlingame, CA.
Y's Therapeutics Co., Limited (Symbol: Private)
Fujiwara Building, 4F, 1-10-11 Ebisu-Nishi, Shibuya-ku Tokyo
Japan, 150-0021
http://www.ysthera.com
| ◈U.S. CONTACT◈ Scott McNinch Director of Business Development, Y's Therapeutics, Inc. +1-650-777-7029 bizdev@ysthera.com |
◈JAPAN CONTACT◈ Yoshio Hioki Director of IP / Licensing & Planning Department, Y's Therapeutics, Co., Ltd. +81-3-5784-2762 bizdev@ysthera.com |
 |
 |
Top |
Site Map | Access Map | Privacy Policy | Terms of Use |
